Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.78 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.60 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363321 | 0.92 | MMP13 (0.77) | MMP13SLC22A8GRK2RECQLMAPK10 | |
| SCHEMBL6363604 | 0.91 | MMP13 (0.78) | MMP13SLC22A8GRK2RECQLMAPK10 | |
| SCHEMBL6360332 | 0.91 | MMP13 (0.80) | MMP13SLC22A8GRK2RECQLMAPK10 | |
| SCHEMBL6440274 | 0.91 | MMP13 (0.64) | MMP13SLC22A8GRK2RECQLMAPK10 | |
| SCHEMBL6360104 | 0.90 | MMP13 (0.81) | MMP13SLC22A8 | |
| SCHEMBL6357989 | 0.88 | MMP13 (0.65) | MMP13SLC22A8RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL6359418 | 0.88 | MMP13 (0.76) | MMP13SLC22A8RECQLMAPK10SMN1; SMN2 | |
| SCHEMBL6359845 | 0.88 | MMP13 (1.00) | MMP13SLC22A8GRK2 | |
| SCHEMBL6358491 | 0.87 | MMP13 (0.79) | MMP13SLC22A8GRK2 | |
| SCHEMBL6363015 | 0.87 | MMP13 (0.77) | MMP13SLC22A8RECQLMAPK10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | WARNER-LAMBERT COMPANY LLC | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085447-A1 | Pyrido[3,4-d]pyrimidine derivatives as matrix metalloproteinase-13 inhibitors | MMP13, MMP9, MMP3 | MMP13 1/4885SLC22A8 2982/4885GRK2 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.